Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aptose Bioscns (APTO)

Aptose Bioscns (APTO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 581,200
  • Shares Outstanding, K 76,273
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,280 K
  • 60-Month Beta 1.68
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.66
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.53
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/05/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.15
  • Number of Estimates 3
  • High Estimate -0.15
  • Low Estimate -0.16
  • Prior Year -0.13
  • Growth Rate Est. (year over year) -15.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.46 +17.96%
on 05/01/20
9.00 -15.33%
on 05/12/20
-0.37 (-4.63%)
since 04/22/20
3-Month
4.27 +78.45%
on 03/17/20
9.00 -15.33%
on 05/12/20
-1.03 (-11.91%)
since 02/21/20
52-Week
1.81 +320.99%
on 06/07/19
9.25 -17.64%
on 02/20/20
+5.64 (+284.85%)
since 05/22/19

Most Recent Stories

More News
Aptose to Present Early CG-806 Clinical Findings at the 25th Congress of the European Hematology Association

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today...

APTO : 7.62 (-2.93%)
Aptose to Present at 2020 RBC Capital Markets Global Healthcare Virtual Conference

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the company...

APTO : 7.62 (-2.93%)
Aptose Biosciences Establishes New At-The-Market Facility

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced...

APTO : 7.62 (-2.93%)
Aptose Reports Results for the First Quarter 2020

CG-806 Phase 1 a/b Study in B Cell Malignancies Now Dosing in Fourth Cohort

APTO : 7.62 (-2.93%)
Could This Be the Medical Breakthrough for The Next Decade

, /PRNewswire/ -- A new medical development is sweeping the country. Some may see it as controversial - but the studies don't lie. It's effective. So effective, in fact, that the FDA has just fast-tracked...

SAGE : 38.94 (+2.53%)
SAVA : 2.13 (+4.41%)
APTO : 7.62 (-2.93%)
AEZS : 1.0891 (-4.88%)
CRHM : 1.8900 (-2.07%)
IIROC Trade Resumption - APS

Trading resumes in:

APTO : 7.62 (-2.93%)
IIROC Trading Halt - APS

The following issues have been halted by IIROC:

APTO : 7.62 (-2.93%)
Aptose Presents Preliminary Clinical Data on CG-806 at AACR Virtual Annual Meeting 2020

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today presented the early clinical...

APTO : 7.62 (-2.93%)
Aptose Biosciences Files Proxy Statement, Announces Online Only Annual General Meeting

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, announced...

APTO : 7.62 (-2.93%)
Aptose to Release First Quarter Ended March 31, 2020 Financial Results and Hold Conference Call on May 5, 2020

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results...

APTO : 7.62 (-2.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade APTO with:

Business Summary

Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in...

See More

Key Turning Points

2nd Resistance Point 8.08
1st Resistance Point 7.85
Last Price 7.62
1st Support Level 7.45
2nd Support Level 7.28

See More

52-Week High 9.25
Last Price 7.62
Fibonacci 61.8% 6.41
Fibonacci 50% 5.53
Fibonacci 38.2% 4.65
52-Week Low 1.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar